Moreover, the efficacy of lenvatinib in Chinese patients with HCC, especially hepatitis B virus-associated HCC, was significantly better than sorafenib, with ORR, PFS, time to disease progression, and OS being 2.6-fold, 2.6-fold, 3.0-fold, and 1.5-fold higher than that of sorafenib, respectively, suggesting that lenvatinib is more suitable for Chinese patients with HCC.[15] Lenvatinib mainly delays HCC progression by inhibiting VEGFRs (VEGFR1, VEGFR2, and VEGFR3) and FGFRs (FGFR1, FGFR2, FGFR3, and FGFR4). Here, KDR is linked to hepatocellular carcinoma.